Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Autologous Neoantigen-Pulsed Dendritic Cell Vaccine (YS247) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07583160 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT07583160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Autologous Neoantigen-Pulsed Dendritic Cell Vaccine (YS247) in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Changhai Hospital
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
June 1, 2026
Completion date
June 1, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer (crpc), metastatic castration-resistant prostate cancer patients, prostate neoplasms